N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer
Both
CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer
Trial Information
Inclusion Criteria:
- Able to tolerated a PET/CT scan
- Age 18 or older
- Patient being considered for XRT for treatment of their cancer
- Able to provide written informed consent
Exclusion Criteria:
- severe claustrophobia or inability to tolerate the PET scan
- pregnant or breastfeeding women
- Patients that need supplemental oxygen
- Patients enrolled in experimental treatments
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia
Outcome Time Frame:
end of study
Safety Issue:
No
Principal Investigator
Robert Jeraj, Ph.D
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Wisconsin, Madison
Authority:
United States: Food and Drug Administration
Study ID:
HSC 2006-0282
NCT ID:
NCT00585117
Start Date:
December 2006
Completion Date:
January 2012
Related Keywords:
- CNS Brain Metastases
- Head and Neck Cancer
- Lung Cancer
- Prostate Cancer
- Esophageal Cancer
- Esophageal Diseases
- Esophageal Neoplasms
- Head and Neck Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Prostatic Neoplasms
- Brain Neoplasms
Name | Location |
|---|---|
| University of Wisconsin Hospital and Clinics | Madison, Wisconsin 53792-0001 |
